Voisin Consulting Life Sciences webinar icon

Patient Engagement Explained: Insights from a Patient, a Patient Association and a Pharmaceutical Company

Post thumbnail Patient Engagement Explained: Insights from a Patient, a Patient Association and a Pharmaceutical Company

Have you wondered about the role of patient engagement in healthcare product development?
Currently, there is a huge emphasis on the importance of using patient experience, preferences and insights. All this in an effort to inform the decision-making process of regulatory authorities and payers.


The Future of Patient Engagement

Both the EMA (European Medicines Agency) and the FDA (Food & Drug Administration) recognize the importance of the patients’ voice in their daily work. Additionally, they are urging healthcare product developers to integrate patient input in their development program.

In a similar way, the EUnet HTA is also committed to involving patients and their representatives in early dialogue. For instance, initiatives include parallel consultation, to capture as early as possible the perspectives on benefit in quality of life and patient reported outcomes.

However, there is still room for industry improvements to optimize collaborations. These should occur along the product development journey, by treating patients as partners.

Patient Engagement Questions Answered

Consequently, this webinar addresses patient engagement from three perspectives: a patient, patient association and industry:

  • What are the real benefits & advances seen in patient engagement? For example, regulatory matters, disease awareness, issues around credibility, information dissemination, health equity, health literacy, etc.
  • Are the specific barriers or limitations encountered?
  • How the collaboration between industry and patients can be improved?
Three Different Perspectives

Hear directly from key stakeholders and experts…

A Patient Association

Firstly, hear from Kathy Oliver, Chair and founding Co-director of the International Brain Tumor Alliance, is a passionate advocate for equal access to new brain therapies worldwide. Moreover, she is highly active on matters of neuro-oncology and rare cancer, and she participates in numerous international committees.

An Industry Member

Secondly, Daniel De Schryver, who is patient engagement and advocacy lead for the EMEA region of the Janssen Pharmaceutical Companies of Johnson & Johnson. His focus has been to continuously improve the company’s relationship with the patient community, while engaging with patients and caregivers to build long-term partnerships and provide better solutions to challenges encountered.

A Patient

Finally, Nadine Grossmann, who is a Ph.D. candidate at Freie Berlin University, who is motivated by personal reasons to advocate and raise awareness about rare disease. Furthermore, she is a board member of 2 patient organizations and is passionate about educating both health care experts and the general public.

Find out more on our unique patient engagement expertise in healthcare product development.

Voisin Consulting Life Sciences download icon

Access the full webinar replay now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    Sample of the webinar

    Featured Speakers

    Nadine Grossmann thumbnail
    Nadine Grossmann
    Patient Advocate, Research Scientist Rare Diseases
    Nadine obtained her Master’s Degree in “Molecular Medicine” and continued her academic career as a Ph.D. candidate in Biochemistry with a focus on the rare disease Fibrodysplasia Ossificans Progressiva (FOP) and bone morphogenetic protein (BMP) signaling in an age-related context. She has a broad education in Molecular Biology, with a specific interest in understanding biomedical aspects of diseases.
    Kathy Oliver thumbnail
    Kathy Oliver
    Chair and Co-Director, International Brain Tumour Alliance (IBTA)
    Kathy Oliver is Chair and Co-Director of the International Brain Tumour Alliance (IBTA), a global network established in 2005 as a dynamic worldwide community for brain tumor patient organizations and others involved in neuro-oncology. Kathy campaigns for equitable access to therapies; encourages the establishment of brain tumor patient/caregiver organizations in countries where they don’t yet exist; and raises awareness of the challenges of this devastating disease. Kathy is the current Co-Chair of the European Cancer Organization’s Patient Advisory Committee and is on the Steering Committee of EURACAN, the European Reference Network for Rare Adult Solid Tumours.
    Daniel De Schryver thumbnail
    Daniel De Schryver
    Patient Engagement & Advocacy Lead, Europe, Middle-East and Africa, Janssen.
    In this function, Daniel is part of a global multi-functional leadership team that helps the company to engage with patients in a systematic way, and helps to build partnerships in developing solutions that better meet the existing needs. He also leads a group of colleagues in the region who play a crucial role in working towards a more collaborative approach in innovation.